These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 15039560)

  • 1. Crystallization and preliminary X-ray analysis of the Plasmodium vivax sexual stage 25 kDa protein Pvs25, a transmission-blocking vaccine candidate for malaria.
    Saxena AK; Saul A; Garboczi DN
    Acta Crystallogr D Biol Crystallogr; 2004 Apr; 60(Pt 4):706-8. PubMed ID: 15039560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preparation, crystallization and preliminary X-ray analysis of a complex between the Plasmodium vivax sexual stage 25 kDa protein Pvs25 and a malaria transmission-blocking antibody Fab fragment.
    Saxena AK; Singh K; Long CA; Garboczi DN
    Acta Crystallogr D Biol Crystallogr; 2004 Nov; 60(Pt 11):2054-7. PubMed ID: 15502325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression, crystallization and preliminary structural analysis of the ectoplasmic region of apical membrane antigen 1 from Plasmodium vivax, a malaria-vaccine candidate.
    Vulliez-Le Normand B; Pizarro JC; Chesne-Seck ML; Kocken CH; Faber B; Thomas AW; Bentley GA
    Acta Crystallogr D Biol Crystallogr; 2004 Nov; 60(Pt 11):2040-3. PubMed ID: 15502321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic diversity of transmission blocking vaccine candidate (Pvs25 and Pvs28) antigen in Plasmodium vivax clinical isolates from Iran.
    Zakeri S; Razavi S; Djadid ND
    Acta Trop; 2009 Mar; 109(3):176-80. PubMed ID: 18950597
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure and mechanism of a transmission blocking vaccine candidate protein Pfs25 from P. falciparum: a molecular modeling and docking study.
    Sharma B
    In Silico Biol; 2008; 8(3-4):193-206. PubMed ID: 19032156
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The surface protein Pvs25 of Plasmodium vivax ookinetes interacts with calreticulin on the midgut apical surface of the malaria vector Anopheles albimanus.
    Rodríguez Mdel C; Martínez-Barnetche J; Alvarado-Delgado A; Batista C; Argotte-Ramos RS; Hernández-Martínez S; González Cerón L; Torres JA; Margos G; Rodríguez MH
    Mol Biochem Parasitol; 2007 Jun; 153(2):167-77. PubMed ID: 17442413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Transmission-blocking vaccine candidate of Plasmodium vivax Pvs25 is highly conservative among Chinese isolates].
    Zheng L; Xu WM; Liu YJ; Yang YM; Cao YM
    Zhongguo Ji Sheng Chong Xue Yu Ji Sheng Chong Bing Za Zhi; 2004 Feb; 22(1):16-9. PubMed ID: 15283259
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequence variation of ookinete surface proteins Pvs25 and Pvs28 of Plasmodium vivax isolates from Southern Mexico and their association to local anophelines infectivity.
    González-Cerón L; Alvarado-Delgado A; Martínez-Barnetche J; Rodríguez MH; Ovilla-Muñoz M; Pérez F; Hernandez-Avila JE; Sandoval MA; Rodríguez Mdel C; Villarreal-Treviño C
    Infect Genet Evol; 2010 Jul; 10(5):645-54. PubMed ID: 20363376
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal and intramuscular immunization with Baculovirus Dual Expression System-based Pvs25 vaccine substantially blocks Plasmodium vivax transmission.
    Blagborough AM; Yoshida S; Sattabongkot J; Tsuboi T; Sinden RE
    Vaccine; 2010 Aug; 28(37):6014-20. PubMed ID: 20637303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure of Fab fragment of malaria transmission blocking antibody 2A8 against P. vivax P25 protein.
    Saxena AK
    Int J Biol Macromol; 2012 Jan; 50(1):153-6. PubMed ID: 22037467
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates.
    Sattabongkot J; Tsuboi T; Hisaeda H; Tachibana M; Suwanabun N; Rungruang T; Cao YM; Stowers AW; Sirichaisinthop J; Coleman RE; Torii M
    Am J Trop Med Hyg; 2003 Nov; 69(5):536-41. PubMed ID: 14695092
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sequence polymorphism in two novel Plasmodium vivax ookinete surface proteins, Pvs25 and Pvs28, that are malaria transmission-blocking vaccine candidates.
    Tsuboi T; Kaslow DC; Gozar MM; Tachibana M; Cao YM; Torii M
    Mol Med; 1998 Dec; 4(12):772-82. PubMed ID: 9990863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Crystallization and preliminary X-ray diffraction studies of leishmanolysin, the major surface metalloproteinase from Leishmania major.
    Schlagenhauf E; Etges R; Metcalf P
    Proteins; 1995 May; 22(1):58-66. PubMed ID: 7675788
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine.
    Miyata T; Harakuni T; Sugawa H; Sattabongkot J; Kato A; Tachibana M; Torii M; Tsuboi T; Arakawa T
    Vaccine; 2011 Mar; 29(15):2720-6. PubMed ID: 21315699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The essential mosquito-stage P25 and P28 proteins from Plasmodium form tile-like triangular prisms.
    Saxena AK; Singh K; Su HP; Klein MM; Stowers AW; Saul AJ; Long CA; Garboczi DN
    Nat Struct Mol Biol; 2006 Jan; 13(1):90-1. PubMed ID: 16327807
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plasmodium vivax gametocyte protein Pvs230 is a transmission-blocking vaccine candidate.
    Tachibana M; Sato C; Otsuki H; Sattabongkot J; Kaneko O; Torii M; Tsuboi T
    Vaccine; 2012 Feb; 30(10):1807-12. PubMed ID: 22245309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cross-reactivity studies of an anti-Plasmodium vivax apical membrane antigen 1 monoclonal antibody: binding and structural characterisation.
    Igonet S; Vulliez-Le Normand B; Faure G; Riottot MM; Kocken CH; Thomas AW; Bentley GA
    J Mol Biol; 2007 Mar; 366(5):1523-37. PubMed ID: 17229439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The use of transgenic Plasmodium berghei expressing the Plasmodium vivax antigen P25 to determine the transmission-blocking activity of sera from malaria vaccine trials.
    Ramjanee S; Robertson JS; Franke-Fayard B; Sinha R; Waters AP; Janse CJ; Wu Y; Blagborough AM; Saul A; Sinden RE
    Vaccine; 2007 Jan; 25(5):886-94. PubMed ID: 17049690
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Purification, crystallization and preliminary X-ray analysis of murine interleukin-5.
    Boodhoo A; Duke NE; Kong D; Ritzel MW; Kunimoto DY; Read RJ
    J Mol Biol; 1994 Aug; 241(2):269-72. PubMed ID: 8057365
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies to Plasmodium vivax transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 do not show synergism.
    Hisaeda H; Collins WE; Saul A; Stowers AW
    Vaccine; 2001 Dec; 20(5-6):763-70. PubMed ID: 11738740
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.